Quetiapine in the treatment of acute mania: Target dose for efficacious treatment

Journal of Affective Disorders

Volumn 100, Issue SUPPL. 1, 2007, Pages

  Vieta, Eduard ^a   Goldberg, Joseph F ^b   Mullen, Jamie ^c   Vågerö, Mårten ^d   Paulsson, Björn ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SILVER HILL HOSPITAL   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Bipolar disorder; Dose; Efficacy; Mania; Quetiapine; Tolerability

Indexed keywords

LITHIUM; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

AKATHISIA; ARTICLE; ASTHENIA; BIPOLAR I DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIA; META ANALYSIS; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 34249276325     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.02.009     Document Type: Article

References (20)

1. Adler C.M., Fleck D.E., Brecher M., and Strakowski S.M. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J. Affect. Disord. 100 (2007) S15-S22 10.1016/j.jad.2007.02.004
2. Arvanitis L.A., and Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry 42 (1997) 233-246
3. Bowden C.L. Dosing strategies and time course of response to antimanic drugs. J. Clin. Psychiatry 57 suppl 13 (1996) 4-9 (discussion 10--2)
4. Bowden C., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., Vågerö M., and Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66 (2005) 111-121
5. Buckley P.F. Effective dosing and dose equivalency of second-generation antipsychotic medications. CNS Spectr. 9 (2004) 24-31
6. Citrome L., and Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatry 10 (2002) 280-291
7. D'Amico M.F., Roberts D.L., Robinson D.S., Schwiderski U.E., and Copp J. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol. Bull. 26 (1990) 147-150
8. Goldberg J.F., Garno J.L., Leon A.C., Kocsis J.H., and Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. J. Clin. Psychiatry 59 (1998) 151-158
9. Maguire G.A., and Phillips G. Optimal dosing of medications (in bipolar disorder). J. Fam. Pract. Suppl. (2003) S22-S25
10. Masand P.S., Fazal F.S., and Patkar A.A. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr. 9 (2004) 16-26
11. McIntyre R.S., Brecher M., Paulsson B., Huizar K., and Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15 (2005) 573-585
12. McIntyre R.S., Konarski J.Z., Jones M., and Paulsson B. Quetiapine in the treatment of acute bipolar mani: Efficacy aross a broad range of symptoms. J. Affect. Disord. 100 (2007) S5-S14 10.1016/j.jad.2007.02.007
13. Sachs G., Chengappa K.N.R., Suppes T., Mullen J.A., Brecher M., Devine N.A., and Sweitzer D.E. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 6 (2004) 213-223
14. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., and Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry 54 (1997) 549-557
15. Vieta E., and Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother. Psychosom. 74 (2005) 10-16
16. Vieta E., Parramon G., Padrell E., Nieto E., Martinez-Arán A., Corbella B., Colom F., Reinares M., Goikolea J.M., and Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. 4 (2002) 335-340
17. Vieta E., Mullen J., Brecher M., Paulsson B., and Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21 (2005) 923-934
18. Woods S.W. The economic burden of bipolar disease. J. Clin. Psychiatry 61 suppl 13 (2000) 38-41
19. Yatham L.N., Paulsson B., Mullen J., and Vagero M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol. 24 (2004) 599-606
20. Yatham, L., Vieta, E., Young, A., Möller, H.-J., Paulsson, B., Vågerö, M., in press. A double-blind, randomized, placebo-controlled trial of quetiapine as add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int. Clin. Psychopharmacol.